Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Abstract Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) a...

Full description

Bibliographic Details
Main Authors: Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Giulia Pierangeli, Carlo Lovati, Marco Aguggia, Florindo d’Onofrio, Alberto Doretti, Paola Di Fiore, Cinzia Finocchi, Renata Rao, Francesco Bono, Angelo Ranieri, Maria Albanese, Sabina Cevoli, Piero Barbanti, for the GARLIT Study Group
Format: Article
Language:English
Published: BMC 2021-05-01
Series:The Journal of Headache and Pain
Subjects:
Calcitonin gene-related peptide
Monoclonal antibodies
Migraine treatment
Real world
Online Access:https://doi.org/10.1186/s10194-021-01247-1

Internet

https://doi.org/10.1186/s10194-021-01247-1

Similar Items